The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers. The world's largest and longest ...
A rigorous study that randomly assigned Parkinson’s patients to take exenatide, a relative of Ozempic, showed absolutely no benefit or slowing of the course of the degenerative disease after 96 ...
A phase 3 randomized controlled trial found no significant improvements with the GLP-1 exenatide in this population. Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo ...
Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...
(HealthDay News) — The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson’s disease severity, according to a study published online Feb. 4 in The ...
FRIDAY, Feb. 7, 2025 (HealthDay News) -- The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity, according to a study published ...
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s disease, finds a new study led by UCL researchers. The world’s largest and ...
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s disease, finds a new study led by UCL Queen Square Institute of Neurology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback